[1]
|
Wang, Y., Wang, Y., Li, J. and Che, G. (2020) Primary Signet-Ring Cell Carcinoma of the Lung: A Report of Seven Cases. Thoracic Cancer, 11, 3015-3019. https://doi.org/10.1111/1759-7714.13614
|
[2]
|
Wang, T., Shen, B., Wang, L. and Liu, F. (2020) Primary Signet Ring Cell Carcinoma of the Breast: A Rare Entity with Unique Biological Behav-ior—A Clinical Study Based on Pure Signet Ring Cell Carcinoma Cohort. Pathology Research and Practice, 216, Article ID: 152948. https://doi.org/10.1016/j.prp.2020.152948
|
[3]
|
Ou, S.H., Ziogas, A. and Zell, J.A. (2010) Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 5, 420-427. https://doi.org/10.1097/JTO.0b013e3181ce3b93
|
[4]
|
Wu, S.G., Chen, X.T., Zhang, W.W., et al. (2018) Survival in Signet Ring Cell Carcinoma Varies Based on Primary Tumor Location: A Surveillance, Epidemiology, and End Results Database Analysis. Expert Review of Gastroenterology & Hepatology, 12, 209-214. https://doi.org/10.1080/17474124.2018.1416291
|
[5]
|
Testori, A., Perroni, G., Carlo, C., et al. (2021) Primary Signet-Ring Cell Carcinoma of the Lung in an HIV-Positive Patient. Thoracic Cancer, 12, 1122-1125. https://doi.org/10.1111/1759-7714.13887
|
[6]
|
Castro, C.Y., Moran, C.A., Flieder, D.G. and Suster, S. (2001) Primary Signet Ring Cell Adenocarcinomas of the Lung: A Clinicopathological Study of 15 Cases. Histopathology, 39, 397-401.
https://doi.org/10.1046/j.1365-2559.2001.01224.x
|
[7]
|
Boland, J.M., Wampfler, J.A., Jang, J.S., et al. (2014) The American Journal of Surgical Pathology, 38, 1681-1688.
https://doi.org/10.1097/PAS.0000000000000280
|
[8]
|
Terada, T. (2012) Primary Signet-Ring Cell Carcinoma of the Lung: A Case Report with an Immunohistochemical Study. International Journal of Clinical and Experimental Pa-thology, 5, 171-174.
|
[9]
|
Danzinger, S., Köstler, W.J., Funovics, M., et al. (2019) Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. Case Reports in Obstetrics and Gynecology, 2019, Article ID: 9461579.
https://doi.org/10.1155/2019/9461579
|
[10]
|
Yoshida, A., Tsuta, K., Watanabe, S., et al. (2011) Frequent ALK Re-arrangement and TTF-1/p63 Co-Expression in Lung Adenocarcinoma with Signet-Ring Cell Component. Lung Cancer, 72, 309-315.
https://doi.org/10.1016/j.lungcan.2010.09.013
|
[11]
|
Hao, Y.Q., Tang, H.P. and Liu, H.Y. (2015) Primary Sig-net-Ring Cell Carcinoma of the Lung Treated with Crizotinib: A Case Report. Oncology Letters, 9, 2205-2207. https://doi.org/10.3892/ol.2015.3003
|
[12]
|
Adderley, H., Blackhall, F.H. and Lindsay, C.R. (2019) KRAS-Mutant Non-Small Cell Lung Cancer: Converging Small Molecules and Immune Checkpoint Inhibition. EBioMedicine, 41, 711-716.
https://doi.org/10.1016/j.ebiom.2019.02.049
|
[13]
|
Takeda, M., Sakai, K., Takahama, T., et al. (2019) New Era for Next-Generation Sequencing in Japan. Cancers (Basel), 11, Article No. 742. https://doi.org/10.3390/cancers11060742
|
[14]
|
Tsuta, K., Ishii, G., Yoh, K., et al. (2004) Primary Lung Carcinoma with Signet-Ring Cell Carcinoma Components: Clinicopathological Analysis of 39 Cases. The American Journal of Sur-gical Pathology, 28, 868-874.
https://doi.org/10.1097/00000478-200407000-00004
|
[15]
|
Pezzuto, A., Terzo, F., Graziani, M.L., et al. (2017) Lung Cancer Requires Multidisciplinary Treatment to Improve Patient Survival: A Case Report. Oncology Letters, 14, 3035-3038. https://doi.org/10.3892/ol.2017.6511
|
[16]
|
Soda, M., Choi, Y.L., Enomoto, M., et al. (2007) Identifica-tion of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. Nature, 448, 561-566. https://doi.org/10.1038/nature05945
|
[17]
|
Rikova, K., Guo, A., Zeng, Q., et al. (2007) Global Survey of Phos-photyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131, 1190-1203. https://doi.org/10.1016/j.cell.2007.11.025
|
[18]
|
Solomon, B.J., Mok, T., Kim, D.W., et al. (2014) First-Line Crizo-tinib versus Chemotherapy in ALK-Positive Lung Cancer. The New England Journal of Medicine, 371, 2167-2177. https://doi.org/10.1056/NEJMoa1408440
|
[19]
|
Hida, T., Nokihara, H., Kondo, M., Kim, Y.H., et al. (2017) Alec-tinib versus Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Ran-domised Phase 3 Trial. The Lancet, 390, 29-39.
https://doi.org/10.1016/S0140-6736(17)30565-2
|
[20]
|
Peters, S., Camidge, D.R., Shaw, A.T., Gadgeel, S., Ahn, A.S., et al. (2017) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New Eng-land Journal of Medicine, 377, 829-838.
https://doi.org/10.1056/NEJMoa1704795
|
[21]
|
Chen, H., Lin, C., Peng, T., et al. (2020) Metformin Reduces HGF-Induced Resistance to Alectinib via the Inhibition of Gab1. Cell Death & Disease, 11, Article No. 111. https://doi.org/10.1038/s41419-020-2307-5
|